Supplementary Table 1.
Baseline characteristics of patients with non-metastatic osteosarcoma.
| Demographic or characteristic | Total patients (N=1000) | Alive cohort (N=797) | Dead cohort (N=203) | |||
|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |
| Age, years | ||||||
| Mean | 25.3 | 23.8 | 31.5 | |||
| Median (range) | 18.0 (3.0–89.0) | 17.0 (3.0–84.0) | 22.0 (3.0–89.0) | |||
| Categorical age | ||||||
| <15 | 316 | 31.6% | 275 | 34.5% | 41 | 20.2% |
| 15–39 | 483 | 48.3% | 385 | 48.3% | 98 | 48.3% |
| >39 | 201 | 20.1% | 137 | 17.2% | 64 | 31.5% |
| Sex | ||||||
| Female | 470 | 47.0% | 383 | 48.1% | 87 | 42.9% |
| Male | 530 | 53.0% | 414 | 51.9% | 116 | 57.1% |
| Race | ||||||
| Black | 150 | 15.0% | 117 | 14.7% | 33 | 16.3% |
| Other | 99 | 9.9% | 78 | 9.8% | 21 | 10.3% |
| White | 751 | 75.1% | 602 | 75.5% | 149 | 73.4% |
| Tumor size, mm | ||||||
| Mean | 96.0 | 93.4 | 106.2 | |||
| Median (range) | 85.0 (5.0–486.0) | 85.0 (5.0–369.0) | 95.0 (14.0–486.0) | |||
| Categorical tumor size | ||||||
| ≤80 mm | 452 | 45.2% | 369 | 46.3% | 83 | 40.9% |
| >80 mm | 548 | 54.8% | 428 | 53.7% | 120 | 59.1% |
| Primary site | ||||||
| Bones of skull and face | 105 | 10.5% | 79 | 9.9% | 26 | 12.8% |
| Bones of upper or lower limb | 823 | 82.3% | 674 | 84.6% | 149 | 73.4% |
| Pelvic bones, sacrum, coccyx | 43 | 4.3% | 22 | 2.8% | 21 | 10.3% |
| Rib, sternum, clavicle | 20 | 2.0% | 15 | 1.9% | 5 | 2.5% |
| Vertebral column | 9 | .9% | 7 | .9% | 2 | 1.0% |
| Grade | ||||||
| Grade I | 58 | 5.8% | 54 | 6.8% | 4 | 2.0% |
| Grade II | 92 | 9.2% | 85 | 10.7% | 7 | 3.4% |
| Grade III | 284 | 28.4% | 216 | 27.1% | 68 | 33.5% |
| Grade IV | 566 | 56.6% | 442 | 55.5% | 124 | 61.1% |
| Histological subtype | ||||||
| Central osteosarcoma | 45 | 4.5% | 42 | 5.3% | 3 | 1.5% |
| Chondroblastic osteosarcoma | 151 | 15.1% | 118 | 14.8% | 33 | 16.3% |
| Fibroblastic osteosarcoma | 59 | 5.9% | 46 | 5.8% | 13 | 6.4% |
| High-grade surface osteosarcoma | 9 | .9% | 7 | .9% | 2 | 1.0% |
| Osteosarcoma, NOS | 599 | 59.9% | 458 | 57.5% | 141 | 69.5% |
| Parosteal osteosarcoma | 67 | 6.7% | 62 | 7.8% | 5 | 2.5% |
| Periosteal osteosarcoma | 19 | 1.9% | 17 | 2.1% | 2 | 1.0% |
| Others | 51 | 5.1% | 47 | 5.9% | 4 | 2.0% |
| AJCC T staging | ||||||
| T1 | 445 | 44.5% | 367 | 46.0% | 78 | 38.4% |
| T2 | 534 | 53.4% | 418 | 52.4% | 116 | 57.1% |
| T3 | 21 | 2.1% | 12 | 1.5% | 9 | 4.4% |
| Radiation | ||||||
| Beam radiation | 51 | 5.1% | 31 | 3.9% | 20 | 9.9% |
| Combination of beam with implants or isotopes | 2 | 0.2% | 2 | 0.3% | 0 | 0.0% |
| None/Unknown | 947 | 94.7% | 764 | 95.9% | 183 | 90.1% |
| Chemotherapy | ||||||
| No/Unknown | 170 | 17.0% | 143 | 17.9% | 27 | 13.3% |
| Yes | 830 | 83.0% | 654 | 82.1% | 176 | 86.7% |
| Survival time | ||||||
| Mean | 46.8 | 51.1 | 29.7 | |||
| Median (range) | 40.0 (0–119.0) | 41.0 (0–119.0) | 25.0 (3.0–89.0) | |||
| Marital status | ||||||
| Married | 209 | 20.9% | 145 | 18.2% | 64 | 31.5% |
| Single/separated/divorced/widowed | 791 | 79.1% | 652 | 81.8% | 139 | 68.5% |
| 9th grade education | ||||||
| Lower 50% | 480 | 48.0% | 393 | 49.3% | 87 | 42.9% |
| Upper 50% | 520 | 52.0% | 404 | 50.7% | 116 | 57.1% |
| High school education | ||||||
| Lower 50% | 496 | 49.6% | 397 | 49.8% | 99 | 48.8% |
| Upper 50% | 504 | 50.4% | 400 | 50.2% | 104 | 51.2% |
| At least bachelor’s degree | ||||||
| Lower 50% | 423 | 42.3% | 335 | 42.0% | 88 | 43.3% |
| Upper 50% | 577 | 57.7% | 462 | 58.0% | 115 | 56.7% |
| Median family income (in tens) | ||||||
| Lower 50% | 496 | 49.6% | 399 | 50.1% | 97 | 47.8% |
| Upper 50% | 504 | 50.4% | 398 | 49.9% | 106 | 52.2% |
| Unemployed | ||||||
| Lower 50% | 459 | 45.9% | 373 | 46.8% | 86 | 42.4% |
| Upper 50% | 541 | 54.1% | 424 | 53.2% | 117 | 57.6% |
| Families below poverty level | ||||||
| Lower 50% | 489 | 48.9% | 392 | 49.2% | 97 | 47.8% |
| Upper 50% | 511 | 51.1% | 405 | 50.8% | 106 | 52.2% |
| Families above poverty level | ||||||
| Lower 50% | 420 | 42.0% | 335 | 42.0% | 85 | 41.9% |
| Upper 50% | 580 | 58.0% | 462 | 58.0% | 118 | 58.1% |
OS – overall survival; CSS – cause-specific survival; AJCC – American Joint Committee on Cancer.